Date:	2022/1/25	
	Meng Chen	
Manuscript Title:	The prognostic valu	ie of circulating lymphocyte counts and ABO blood group in lung cancei
stereotactic body r	adiation therapy: A ret	rospective study
Manuscript numbe	r (if known):	
•	,	
In the interest of tr	ansparency, we ask you	u to disclose all relationships/activities/interests listed below that are
related to the cont	ent of your manuscript	. "Related" means any relation with for-profit or not-for-profit third
parties whose inter	rests may be affected b	by the content of the manuscript. Disclosure represents a commitment
	•	,
to transparency an	d does not necessarily i	indicate a bias. If you are in doubt about whether to list a

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

relationship/activity/interest, it is preferable that you do so.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending meetings and/or travel	XNone			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	XNone			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	XNone			
_					
12	Receipt of equipment,	XNone			
	materials, drugs, medical				
	writing, gifts or other				
12	services	V Name			
13	Other financial or non- financial interests	XNone			
	illianciai illierests				
Dla -		uflick of interest in the fel	laudaa kau		
riea	Please summarize the above conflict of interest in the following box:				

Please place an "X" next to the following statement to indicate your agreement:

None

Date:	2022/1/25	
<b>Manuscript Title:</b>		circulating lymphocyte counts and ABO blood group in lung cancer
Manuscript num	ber (if known):	<del>-</del>
related to the corparties whose into transparency a	ntent of your manuscript. "Rel terests may be affected by the	disclose all relationships/activities/interests listed below that are elated" means any relation with for-profit or not-for-profit third e content of the manuscript. Disclosure represents a commitment ate a bias. If you are in doubt about whether to list a hat you do so.
The following qu manuscript only.	• • •	relationships/activities/interests as they relate to the <u>current</u>
to the epidemiol	•	should be <u>defined broadly</u> . For example, if your manuscript pertainuld declare all relationships with manufacturers of antihypertensive ationed in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	X_None	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	ectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	The second secon		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Descript of a surject set	V None	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plea	ise summarize the above co	nflict of interest in the fo	llowing box:

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/1/25
	Shuling Li
Manuscript Title: stereotactic body r	The prognostic value of circulating lymphocyte counts and ABO blood group in lung cancer adiation therapy: A retrospective study r (if known):
related to the conto parties whose inter to transparency and	ansparency, we ask you to disclose all relationships/activities/interests listed below that are ent of your manuscript. "Related" means any relation with for-profit or not-for-profit third rests may be affected by the content of the manuscript. Disclosure represents a commitment d does not necessarily indicate a bias. If you are in doubt about whether to list a cy/interest, it is preferable that you do so.
The following ques manuscript only.	tions apply to the author's relationships/activities/interests as they relate to the <u>current</u>
The author's relation	onships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertain

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
			planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials, medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
	The time initial to this item.		
		Time frame: past	36 months
2	Grants or contracts from	X None	30 months
_	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X None	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events	V N			
6	Payment for expert	XNone			
	testimony				
7	Support for attending	X None			
,	meetings and/or travel	^_None			
8	Patents planned, issued or	XNone			
	pending				
9	Participation on a Data	XNone			
	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	X_None			
	in other board, society, committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	X None			
11	Stock of Stock options	XNOTIC			
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	XNone			
	financial interests				
Plea	Please summarize the above conflict of interest in the following box:				

-

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/1/25
	Yinnan Meng
stereotactic body r	The prognostic value of circulating lymphocyte counts and ABO blood group in lung cancer radiation therapy: A retrospective study er (if known):
related to the cont parties whose inte to transparency an	ransparency, we ask you to disclose all relationships/activities/interests listed below that are ent of your manuscript. "Related" means any relation with for-profit or not-for-profit third rests may be affected by the content of the manuscript. Disclosure represents a commitment d does not necessarily indicate a bias. If you are in doubt about whether to list a ty/interest, it is preferable that you do so.
The following ques	tions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	XNone		
	testimony			
_				
7	Support for attending meetings and/or travel	XNone		
8	Patents planned, issued or	XNone		
	pending			
9	Participation on a Data	XNone		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	XNone		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid	V. Nene		
11	Stock or stock options	XNone		
12	Receipt of equipment,	X None		
12	materials, drugs, medical	NNOTIC		
	writing, gifts or other			
	services			
13	Other financial or non-	XNone		
	financial interests			
Plea	Please summarize the above conflict of interest in the following box:			

-

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/1/25	
Your Name:	Yangyang Shi	
	The prognostic value of circulating lympho adiation therapy: A retrospective study	cyte counts and ABO blood group in lung cancer
Manuscript number	r (if known):	
related to the conte parties whose inter	ent of your manuscript. "Related" means any ests may be affected by the content of the ma	anuscript. Disclosure represents a commitment
• •	d does not necessarily indicate a bias. If you a y/interest, it is preferable that you do so.	re in doubt about whether to list a

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Command for additional	V Nove	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
11	Stock of Stock options	XNOTIE	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Plas	se summarize the above co	nflict of interest in the fol	lowing hox:
	ise sammanize the above to	or micercal in the lot	

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/1/25	
Your Name:	Xiaofeng Chen	
•	The prognostic value of circulating lymphocyte counts and ABO blood group in lung candradiation therapy: A retrospective study	cer
Manuscript numb	er (if known):	_
In the interest of	ransparency, we ask you to disclose all relationships/activities/interests listed below that ar	e

related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present	XNone	
	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid	V 1	
11	Stock or stock options	XNone	
12	Receipt of equipment,	X None	
12	materials, drugs, medical	^_NONE	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Dlas	sa summariza tha ahaya sa	uflict of intovect in the fall	owing hove

Please summarize the above conflict of interest in the following box:

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/1/2	5					
You	Your Name: Haihua Yang						
	Manuscript Title: The prognostic value of circulating lymphocyte counts and ABO blood group in lung cancer						
	eotactic body radiation ther						
Mar	nuscript number (if known):						
relate part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are ins any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a so.				
	following questions apply to uscript only.	o the author's relationship	s/activities/interests as they relate to the <u>current</u>				
to th	• -	nsion, you should declare a	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.				
	em #1 below, report all sup time frame for disclosure is	·	in this manuscript without time limit. For all other items,				
		Name all entities with	Specifications/Comments				
		whom you have this	(e.g., if payments were made to you or to your				
		relationship or indicate	institution)				
		none (add rows as					
		needed) Time frame: Since the initia	nlanning of the work				
1	All support for the present	X None	planning of the work				
-	manuscript (e.g., funding,	NONE					
	provision of study materials,						
	medical writing, article						

Time frame: past 36 months

X\_None

X\_\_None

\_X\_\_None

processing charges, etc.)

No time limit for this item.

Grants or contracts from

in item #1 above).

Consulting fees

Royalties or licenses

any entity (if not indicated

2

3

4

5	Payment or honoraria for lectures, presentations,	XNone						
	speakers bureaus,							
	manuscript writing or							
	educational events	V N						
6	Payment for expert	XNone						
	testimony							
7	Support for attending	X None						
,	meetings and/or travel	^None						
	meetings and of travel							
8	Patents planned, issued or	XNone						
	pending							
9	Participation on a Data	XNone						
	Safety Monitoring Board or							
	Advisory Board							
10	Leadership or fiduciary role in other board, society,	X_None						
	committee or advocacy group, paid or unpaid							
11	Stock or stock options	X None						
11	Stock of Stock options							
12	Receipt of equipment,	X None						
	materials, drugs, medical							
	writing, gifts or other							
	services							
13	Other financial or non- financial interests	XNone						
Plea	Please summarize the above conflict of interest in the following box:							

-

None			

Please place an "X" next to the following statement to indicate your agreement: